Lead discovery and optimization of T-type calcium channel blockers

Bioorganic & Medicinal Chemistry
2007.0

Abstract

A series of compounds were designed as T-type calcium channel blocker containing 6 or 5 pharmacophore features from structure-based virtual screening. To optimize the suggested structure, over 130 derivatives were synthesized and their inhibitory activities on T-type calcium channel were assayed using in vitro screening system with alpha1(G) and alpha1(H) clones. For the compounds with higher activities in FDSS assay system, the efficacy was measured by patch-clamp method. Among the library with 5 features, alkaneamide derivatives (7b, 9j, 11b, 11g, 11h) with 4-arylsubstituted piperazine showed better IC(50) values than Mibefradil.

Knowledge Graph

Similar Paper

Lead discovery and optimization of T-type calcium channel blockers
Bioorganic & Medicinal Chemistry 2007.0
Synthesis and evaluation of α,α′-disubstituted phenylacetate derivatives for T-type calcium channel blockers
Bioorganic & Medicinal Chemistry Letters 2008.0
Novel T-type calcium channel blockers: Dioxoquinazoline carboxamide derivatives
Bioorganic & Medicinal Chemistry 2007.0
Design, synthesis, and biological evaluation of 1,3-dioxoisoindoline-5-carboxamide derivatives as T-type calcium channel blockers
Bioorganic & Medicinal Chemistry Letters 2007.0
Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers
Bioorganic & Medicinal Chemistry Letters 2010.0
Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers
Bioorganic & Medicinal Chemistry Letters 2013.0
3D pharmacophore based virtual screening of T-type calcium channel blockers
Bioorganic & Medicinal Chemistry 2007.0
Synthesis and biological evaluation of novel T-type calcium channel blockers
Bioorganic & Medicinal Chemistry Letters 2007.0
3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers
Bioorganic & Medicinal Chemistry Letters 2004.0
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor
Bioorganic & Medicinal Chemistry Letters 2013.0